NCT03131895View on ClinicalTrials.gov

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

July 3, 2017

Study Completion Date

July 31, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

30 mg dexlansoprazole capsules manufactured at TOB

Dexlansoprazole delayed-release.

DRUG

30 mg dexlansoprazole capsules manufactured at TPC

Dexlansoprazole delayed-release.

DRUG

60 mg dexlansoprazole capsules manufactured at TOB

Dexlansoprazole delayed-release.

DRUG

60 mg dexlansoprazole capsules manufactured at TPC

Dexlansoprazole delayed-release.

Trial Locations (1)

84106

PRAHS Phase 1 unit, Salt Lake City

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03131895 - Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants | Biotech Hunter | Biotech Hunter